Michele Maholtz, MD
Pulmonary Disease · Vero Beach, FLNPI 1205807161
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,612 and has fallen 95.6% since, to $115 in 2025.
Across 218 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$544
- Boehringer Ingelheim$541
- Mylan Specialty L.p.$494
- AbbVie$445
- GSK$390
- Grifols USA, LLC$259
- plus $2K from 22 others
Across 3 payments — averaging $0.00 each. An ownership or investment interest held by the physician or an immediate family member.
- SWAN Valley Medical Incorporated$0
What the payments were for
- Food & beverage$4,39399%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $544 |
| Boehringer Ingelheim | 24 | $541 |
| Mylan Specialty L.p. | 19 | $494 |
| AbbVie(2 entities) | 14 | $445 |
| GSK | 25 | $390 |
| Grifols USA, LLC | 23 | $259 |
| Genentech USA, Inc. | 17 | $206 |
| Sanofi | 8 | $184 |
| Sunovion Pharmaceuticals Inc. | 8 | $154 |
| Bayer | 2 | $142 |
| Harmony Biosciences LLC | 4 | $135 |
| Shire North American Group Inc | 6 | $118 |
| Boston Scientific | 2 | $101 |
| Actelion Pharmaceuticals US, Inc. | 4 | $98 |
| Advanced Respiratory, Inc | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 6 | $84 |
| Medline Industries LP | 1 | $83 |
| Insmed, Inc. | 3 | $65 |
| Pfizer | 2 | $53 |
| Circassia Inc. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| CSL Behring | 2 | $34 |
| Philips North America LLC | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Nabriva Therapeutics, PLC | 1 | $25 |
| Electromed, Inc. | 1 | $16 |
| Next Science LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,443 in reported general payments places this provider in the 55th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 16 | $551 |
| Mupirocin | 55 | $462 |
| Doxycycline Hyclate | 16 | $186 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Vero Beach
- Diego MaldonadoVero Beach$254K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.